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Introduction
The macula is a specialised part of the central retina
which is responsible for optimal spatial and colour vision.
Age-related macular degeneration (AMD) is the leading cause
of blind registration in the western world (Bressler 2004).
Epidemiological studies carried out in different countries
have been remarkably consistent in demonstrating that
the prevalence of eye disease, and associated vision loss, is
critically age-dependent (Bunce & Wormald 2008; Kelliher
et al. 2006). Indeed, for each decade over the age of 40 years,
the amount of blindness and vision loss increases threefold.
Interestingly, in developed countries, 48% of all cases of blind
registration in persons aged 40 years and over are attributable
to AMD. AMD is seen in about 2% of the 70–80-year-old
age group, 4% in the 81–84-year-old age group and 13% in
those aged 85 years and older. It has been estimated that
there are currently 80 000 people in the Republic of Ireland
(http://www.fightingblindness.ie/) and 417 000 people in the
UK (Owen et al. 2003) suffering with AMD and these figures are
expected to double by 2020. In fact, the most recent analysis
of the blindness register in the Republic of Ireland revealed that
the number of persons registered blind as a consequence of
AMD more than doubled (113% increase) in the short period
from 1996 to 2003 (Kelliher et al. 2006). A similar increasing
trend has also been noted in the UK, where AMD was observed
to account for 29% of blindness registrations in 1980, but
increased to 52% by 1997 (Bamashmus et al. 2004). Given our
ever-increasing life expectancy, these upward trends in AMD
prevalence and associated blindness are certain to continue,
and will cement AMD’s position as the most significant
sight-threatening condition likely to affect the growing, and
ageing, population in the UK and Ireland.
The impact of vision loss, secondary to AMD, manifests as
reduced ability to drive, to read, to recognise faces or to
perform routine daily visual tasks. There is also a consequential
loss of social independence, which is increasingly problematic
in an era of declining family support and lengthening periods
of retirement. When asked what health condition they fear
most, one-third of people will identify blindness, another third
will identify cancer and the final third will identify a wide range
of ailments or fears. Most people, however, regard it as unlikely
that they will ever develop blindness or visual impairment.
Indeed, health policy-makers often regard vision loss as being of

relatively minor importance or priority. It is worth emphasising
that even small degrees of visual impairment have important
adverse impacts on both the quality and length of life. For
example, vision of 6/12 or less is associated with the following:
loss of driving licence; increased risk of falls, hip fractures and
depression; loss of social independence; admission to a nursing
home 4 years before their counterparts with normal vision;
and perhaps most importantly, a reduced ability to enjoy
healthy and independent ageing. Such consequences of vision
loss are not only costly to the individual in personal terms,
they also have significant direct and indirect financial cost
implications to the exchequer – costs that continue to escalate.
The aetiology of AMD is poorly understood, yet there
is consensus that genetic background and certain
environmental/lifestyle risk factors (eg smoking) and their
interaction predispose an individual to the condition (Schork
1997). Current treatment interventions, such as anti-vascular
endothelial growth factor agents, have resulted in better
outcomes for patients with neovascular AMD (Bressler et
al. 2010; Brown et al. 2009; Rosenfeld et al. 2006). These,
however, are costly and cumbersome to the healthcare provider
and patient. In addition, there is no effective treatment for
the atrophic (dry) form of late AMD, which has a similarly
detrimental effect on a patient’s quality of life.
The dietary carotenoids lutein (L), zeaxanthin (Z), and
meso-zeaxanthin (meso-Z) accumulate at the macula where
they are collectively known as macular pigment (MP) and give
the macula its yellow appearance. L and Z can be obtained
from many foods (Sommerburg et al. 1998), whereas meso-Z
is not present in a conventional western diet, although it can
be found in certain types of seafood (Maoka et al. 1986).
MP has generated interest in recent years because of its
possible protective role in AMD, putatively attributable to its
antioxidant properties and/or its prereceptoral filtration of
damaging short-wavelength (blue) light (Beatty et al. 2000a;
Tomany et al. 2004).
In summary, AMD, which is already at epidemic levels, will
continue to increase in prevalence with the ageing and
growing population. AMD destroys central vision and impairs
quality of life in the elderly. Current treatment options, while
effective in some patients, are costly and present a massive
and increasing financial challenge for healthcare services
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Results and discussion

worldwide. There is a clear need, therefore, for attention to be
directed towards the prevention of AMD and its progression.
The optometrist, who represents the first line of eye care, is
uniquely placed to implement such a prevention strategy for
AMD. However, it appears that current ophthalmic practice
for AMD assessment and prevention may be failing to
exploit the latest technological developments and scientific
knowledge. It is not clear what methods, if any, are being used
to identify patients at risk of AMD, or what preventive methods,
if any, are being utilised to help reduce risk of AMD and its
progression. This investigator-driven, online AMD research
study was designed to address these precise questions for a
target population consisting of optometrists in the Republic of
Ireland and the UK.

The 11 questions posed to optometrists as part of this online
research study are presented in Table 1.
The majority of practices (81%) reported patient numbers of
5000 per year or less. The reported percentage of patients
presenting with AMD ranged from 0 to 90% (Figure 1). The
mean ± standard deviation (SD) percentage of patients
presenting with AMD was 10.8 ± 10.8. However, some practices
reported much higher percentages presenting with AMD. For
example, of the 724 practice respondents, 65 reported AMD
prevalence in excess of 20% among practice attendees.
The Amsler grid was the most widely reported technique used
routinely to check for the presence of AMD (35%). The range
of additional techniques employed to detect the presence of
AMD can be seen in Figure 2.

Methods

The Institute of Vision Research (IVR), based in Waterford,
Ireland, initiated and designed the current research study. The
survey questions asked as part of this online AMD research
study (all presented below in the Results section of this report)
were prepared by members of the IVR with expertise and input
from the following disciplines: ophthalmology, optometry,
vision science, nutrition and statistics.

Number of practices

500

300
200
100

Figure 2. Reported routine age-related macular
degeneration (AMD) and AMD risk assessment techniques.

200

Mean = 10.79
Std. Dev. = 10.831
N = 724

Number of practices

150

100

50

0

0

20

40

60

Reported percentage of patients presenting with AMD

Figure 1. Reported percentage of patients presenting with signs of age-related macular degeneration (AMD).
136

Optical coherence
tomography

Risk assessment

Volk examination

Ophthalmoscopy

Measurement of
macular pigment

Fundus
photography

0

Amsler grid

The Association of Optometrists in Ireland and the
College of Optometrists in the UK were informed of the study
and its objectives, and agreed to contact (by email) their
members and invite them to participate in the online AMD
survey. Seven hundred and fifty emails were circulated in
Ireland and 8049 emails were circulated in the UK. Reminder
emails were sent to Association and College members after
6 weeks. The survey was open to members for a total of
3 months. In total, 724 respondents (8.2%) completed and
submitted the survey online.

400

80
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1

What is your average annual
patient number?

2

Approximately what percentage of
your patients present signs of AMD?

3

What assessments do you routinely
perform to check for the presence of
AMD and/or risk of developing AMD?

4

If you measure macular pigment,
which device do you use?

5

Do you currently recommend eye
supplements for patients with AMD?

6

Do you currently recommend eye
supplements for patients at risk of
developing AMD?

Within the last 12 months,
approximately how many patients
have you noticed, or the patients
themselves have reported, an
improvement in their AMD following
recommendation of the eye
nutritional supplement?

Although 16% of respondents to question 3 indicated
that measurement of MP comprised part of their routine
investigations for AMD, only 3.7% (27 practices) named the
MP measurement device they used in response to question 4.
Of these, 13 use the Macuscope device, 13 use the Mpod, and
one uses the Zeiss Visucam 200. In addition, one respondent
reported measuring MP using an ophthalmoscope, and one
respondent reported using a Friedmann analyser; however,
these devices are not suited to measure MP.

Visivite

11

Nutrivision

Within the last 12 months,
approximately how many patients
have you recommended eye
supplements to?

Vitalux

10

Viteyes

What factors influence your decision
to recommend eye supplements,
if any?

Ocuvite Preservision

9

0

Ocuvite Lutein

What is your main reason for not
recommending supplements?

100

Other

8

200

Macushield

Which supplements do you
recommend for AMD?

300

ICaps

7

400

Number of practices

Question no. Question

A significant majority of practices (90.6%) are currently
recommending eye supplements for patients with
established AMD. In addition, 73.2% of respondents indicated
that they are currently recommending eye supplements
for patients at risk of AMD. ICaps (382 practices, 52.8%)
and Macushield (351 practices, 48.5%) are the most
recommended supplements for AMD (Figure 3). In those
practices recommending only a single supplement, ICaps and
Macushield again predominate (Figure 4).

Figure 3. Supplements recommended in optometry
practices for age-related macular degeneration. Note that
many practices recommend more than one supplement,
and therefore the cumulative counts add up to more than
the total number of survey respondents.
150

Number of practices

Table 1. Online questionnaire items

100

50

0

ICaps

Macushield

Ocuvite Lutein

Ocuvite
Preservision

Other

Figure 4. Supplement recommendations in practices
recommending a single supplement.
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Strong scientific evidence was cited as the principal reason
supporting the recommendation of supplements for AMD
(Figure 5).
Number of practices

500

400

Number of practices

400

300

300

200

100
200

0

100

0

Strong scientific
evidence

Good branding

Good value for money

Good salesperson

Figure 5. Reasons cited for recommending supplements for
age-related macular degeneration.
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Number of practices

40

30

Patients with early
AMD with no
affected vision
(i.e. drusen;
pigmentary
changes)

Patients with early
AMD with affected
vision (wet type)

Patients at known
risk of developing
AMD with no
affected vision
(e.g. family history,
cigarette smoker)

Figure 7. Reasons for prescribing eye supplements. AMD,
age-related macular degeneration.
For the majority of practices, supplements were recommended
for fewer than 50 patients in the preceding 12 months,
while only a small minority of respondents estimated a
recommendation rate greater than 200 (Figure 8).
250

200

Number of practices

In the small number of practices (9.4%) not currently
recommending such supplements, the reasons for not
recommending them were more evenly dispersed, although
interestingly, lack of scientific evidence was the most common
reason given (Figure 6).

Patients with
advanced AMD
with affected vision
(dry type)

150

100

50
20

0

21 to 50

1 to 20

51 to 100

None

101 to 150

200+

151 to 200

10

0

No scientific
evidence

Cost

Not practice
policy

Too time
consuming

Other

Figure 6. Reasons cited by practices not recommending
supplements for age-related macular degeneration.
Presence of clinical signs of the atrophic form of late AMD
(including vision loss) was the strongest influencing factor
involved in clinical decisions to recommend AMD supplements
to a patient. This was closely followed by the presence of
early AMD, including signs such as drusen and/or pigmentary
changes at the macula, but without significant vision loss.
Increased risk of developing AMD was the least commonly
cited reason for prescribing supplements (Figure 7).
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Figure 8. Estimated number of patients to whom eye
supplements were recommended in the preceding
12-month period.
In total, 22% (158) of practices reported some form of
improvement in at least one of their AMD patients following
supplementation (Figure 9). For these practices, patient
improvement was noted, on average, in 9% (±11%) of
patients to whom supplements had been recommended.
For the majority of cases, it was not possible to assign these
improvements to any one particular supplement. This was
possible, however, for the 265 practices, identified through
the survey, that recommend a single supplement, thereby
enabling a determination of the relative efficacy of individual
supplement types.
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the UK and Ireland. It should also be recognised that some
inconsistencies and irregularities in response have been
noted, including the number of practices reporting that they
measure MP versus the number of respondents who named
the MP device routinely used. Also, the responses to question
3 remain somewhat puzzling, with only a minority of
respondents indicating the use of fundus evaluation
(ophthalmoscopy, Volk biomicroscopy or fundus photography)
to assess for the presence of signs of AMD.

Number of practices

100
80
60
40
20
0

ICaps

Macushield

Ocuvite Lutein

Ocuvite
Preservision

Other

Supplement

Figure 9. Estimated percentage of patients showing
improvement in age-related macular degeneration following
supplementation. *Statistical outliers.
The differences in reported improvement across supplement
types are presented in Table 2. Treating reported improvement
as a simple binary variable (ie yes/no improvement response),
Pearson chi-squared analysis reveals a statistically significant
difference between the relative improvement between
supplements (Pearson chi-squared test, P = 0.008). Of note,
in Table 2 the reported improvement is highest amongst those
practices using Macushield (the only supplement containing
meso-Z: see below for discussion on this interesting finding).
Further statistical analysis of the actual reported percentage
improvement for each practice also reveals a significant
difference between supplement types (Kruskal–Wallis test,
P = 0.031). Once again, the percentage improvement is highest
in those practices that recommend Macushield exclusively.
These findings are illustrated in Figure 9.
Table 2. Improvement in age-related
degeneration reported for supplements

macular

Improvement noticed
Supplement

No

Yes

Total

ICaps

66

46

112

Macushield

42

68

110

Ocuvite Lutein

6

6

12

Ocuvite Preservision

5

5

10

Other

15

6

21

Discussion
This online AMD research study was uniquely designed to
investigate current practice for AMD assessment, therapeutic
and prevention strategies amongst the optometric
communities in the Republic of Ireland and the UK. While the
number of respondents (n = 724) and response rate (5.27%)
are typical of modern online surveys, and remain sufficient
for reliable statistical interpretation of the results contained
herein, it should be recognised that the responses described
may not be wholly reflective of optometric practice across

Interestingly, the average number of patients presenting
with signs of AMD was indicated to be around 10%.
Importantly, as the question about the number of patients
per annum included all patients, of all ages, a figure of 10%
appears somewhat high, but is consistent with the increasing
prevalence of AMD in the ageing population, and also with
the likely age profile of patients attending optometry practice,
which would tend to be skewed to older age. Also, and of
interest, a large number of practices reported an extremely
high number of people presenting with signs of AMD. This
finding is most likely explained by a particularly older age
patient profile in these particular practices. This survey did not
differentiate the type of practice worked in by the respondents,
and it should be recognised that this could influence the
high estimated AMD prevalence reported here (for example,
if a high percentage of hospital eye service optometrists
responded to the survey).
When asked what assessments they routinely perform to check
for the presence of AMD and/or risk of their patients developing
this condition, it was interesting to note that the Amsler grid
was the most commonly reported technique to be used
(35%). The low response rate for ophthalmoscopy (14%), Volk
examination (8%) or fundus photography (16%) would seem
highly surprising, especially given that it is expected that at
least one of these techniques would be used during the course
of every optometric eye examination, particularly among those
patients at risk of developing AMD. While it is encouraging to
see newer technologies such as optical coherence tomography
(OCT) in use, such techniques could not yet be regarded as
routine for optometric practice. Of more concern, however,
are the low numbers of practitioners (7%) who report that
they routinely perform an AMD risk assessment. Given the
nature of the condition, and the treatment options available, it
appears sensible that efforts should be made to detect risk of
this condition before the disease is allowed to manifest.
MP, made up of the dietary carotenoids L, Z and meso-Z, is now
believed to play an important role in eye health, particularly
for AMD. Indeed, the protective role of this pigment lies in
its ability to function as a powerful antioxidant (Beatty et al.
2000b) and as a prereceptoral filter of potentially damaging,
short-wavelength blue light (Haegerstrom-Portnoy 1988). It
is now accepted that free radical damage caused by oxidative
stress, which is exacerbated by irradiation of the retina with
blue light, is aetiologically important in AMD. It makes sense,
therefore, that an individual’s MP is key to reducing these
stresses that ultimately lead to AMD (Loane et al. 2008).
It is interesting to note that only a very small percentage of
practices (3.7%) currently have the capacity to measure this
important dietary pigment for people with, or at risk of, AMD.
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Given that this pigment is modifiable by dietary refinement
and/or supplementation with the macular carotenoids, and
given that enrichment of this pigment is believed to confer
protection against AMD, optometrists are now advised to
recommend dietary supplements to patients with, or at risk
of, AMD. However, it is important that the eye care specialist
endeavours to identify response to such dietary modification
or supplementation, which can only be achieved by measuring
this pigment in vivo. This is important as it is also known that
not all individuals respond to supplementation. There are many
different supplements available, containing many different
formulations and concentrations of the macular carotenoids.
Poor or slow response to one supplement might warrant
change in recommendation to an alternative supplement.
We believe that the reason for such a small number of eye care
specialists in the Republic of Ireland and the UK measuring this
pigment is due to the technology that has been available up
to now. Indeed, the current accepted gold standard within the
scientific community for measuring MP is a technique known
as heterochromatic flicker photometry (HFP). It is our view that
this subjective technique, which requires customisation of the
method and training for the patients, has only been suitable
for scientific studies (given the length of time required to
customise the stimulus and train the patient – circa 20 minutes
per patient). Commercial organisations have tried to promote
‘clinical’ versions of this flicker technique for the optometrist;
however, this has not been successful, as confirmed by the
current survey results showing the very small number of
practices actually using their techniques. For example, the
Macuscope uses a type of HFP to measure MP, but fails to allow
for customisation of the method. This, in our opinion, results
in a far too difficult and unreliable measurement. Another
instrument, the M-POD, which again uses a type of HFP to
measure MP, has significantly improved the measurement
technique. It can, however, occasionally prove difficult for
some patients, and tends to yield lower results compared to
the gold-standard device. A new device, known as the clinical
densitometer, appears to have successfully addressed most of
the earlier problems with the measurement of MP in clinical
practice, and produces reliable and reproducible results that, in
our opinion, have the potential to bring value to the optometry
community and its patient base. Importantly, using these
newer technologies, this measurement now takes only a few
minutes to perform and the data obtained are reliable, making
it suitable for the clinical setting.
It was no surprise to see that over 90% of practices currently
recommend some form of nutritional eye supplement.
Interestingly, when asked if they recommend supplements
for patients at risk of AMD (ie currently not presenting with
disease but believed to be at risk due to a positive family
history or other combined risk profile), it was encouraging to
see a high percentage of practices (n > 70%) making such a
recommendation. This recommendation is consistent with
the scientific view that risk reduction for AMD, which includes
retinal enrichment with the macular carotenoids, needs to be
established before the disease is allowed to develop to achieve
maximum effect. Indeed, given that AMD is the result of
cumulative and chronic damage caused by free radicals over a
person’s lifetime, it makes sense that preventive methods are
implemented during this same time period.
140

Given the estimated percentage of patients with AMD
attending for optometric examination (10.8%), it is perhaps
surprising to note the relatively low rates of recommendation
of nutritional supplements. For the majority of practices,
the estimated number of recommendations is less than one
per week, with very few practices reporting more than four
recommendations per week. Given the prevalence of AMD, the
likely age profile of patients attending optometry practices,
and the prevalence of confirmed risk factors for AMD such as
smoking, this likely represents a significant underexploitation
of nutritional supplementation for AMD and AMD risk.
In response to the question as to what actual type (brand)
of supplement was recommended, the results clearly show
that ICaps (containing 10mg L/Z plus antioxidants) and
Macushield (containing 10mg L, 10 mg meso-Z and 2 mg Z) are
the two leading choices amongst the optometry communities
in the Republic of Ireland and the UK. Of the 724 respondents,
382 recommend ICaps and 351 recommend Macushield, and
these remain the most commonly recommended supplements
regardless of whether practices stock just one or more than
one supplement.
When queried on the reasons for recommending their chosen
eye supplement over others, ‘strong scientific evidence’
was the main reported reason for supplement choice. It
appears, therefore, that the optometry community in the
Republic of Ireland and the UK feels that the supplements
they recommend (ie mainly ICaps and Macushield) have the
most scientific support to justify such recommendations.
However, it is important to point out that, for the leading
recommended supplement, ICaps, this is not the case. This
point is supported by the fact that, to our knowledge, there is
not a single published scientific study in the literature that has
commented on response, safety and/or suitability of the ICaps
supplement for patients with or at risk of AMD. In contrast,
however, the Ocuvite Lutein supplement has, indeed, many
supporting published studies commenting on the suitability of
this supplement for patients with or at risk of AMD (Loughman
et al. 2010; Nolan et al. 2011; Trieschmann et al. 2007). The
second most recommended supplement, Macushield, also
has a growing body of scientific evidence in support of this
particular supplement for patients with or at risk of AMD
(Bone et al. 2007; Connolly et al. 2010).
There are many different types of L available (eg free versus
ester), in different formulations and concentrations, which
may influence how the patient responds to the supplement.
It is important, therefore, that the optometrist is informed
of these facts, and understands that patients’ response to
supplements is not consistent across the many supplements
available. In summary, therefore, the optometrist is advised
to seek appropriate scientific data (eg from clinical trials)
providing information on response, safety of consumption
and efficacy for AMD when deciding on which supplement to
recommend to patients.
The final objective of this research survey was to try and
identify whether signs and symptoms of AMD were improved
in patients using supplements recommended by the practice
(optometrist). Although this aspect required respondents
to make a subjective analysis of their clinical experience of

Online AMD research study for optometrists: current practice in the Republic of Ireland and UK

supplementation (question 11), robust statistical analysis
confirmed that there was a statistically significant difference
with respect to the reported efficacy of supplements, which
was dependent on the actual supplement recommended, and
was in favour of Macushield. This finding, albeit provocative,
is important given that Macushield is the only commercially
available supplement that contains all three of the macular
carotenoids, including the central carotenoid, meso-Z. Indeed,
the view of these clinical optometrists is consistent with
recently published scientific studies which confirm significant
enrichment of MP in individuals following supplementation with
this particular carotenoid supplement (Connolly et al. 2010).
It is also consistent with a recently published study confirming
the enhanced antioxidant capacity of the carotenoids when
all three are present in formulation (as opposed to any of
the individual carotenoids at the same concentration)
(Li et al. 2010).
This online AMD research survey has provided valuable
information as to current practice amongst Irish and UK
optometrists for AMD. It is clear from this survey that AMD
continues to present a challenge to the optometry community.
Current methods to assess and manage risk of AMD are
improving; however, the optometrist is advised to consider
advanced technologies such as OCT, and in particular, to
consider incorporating the measurement of MP into routine
optometric practice. This should form part of an overall formal
AMD risk assessment strategy, aimed at identifying those
patients at highest risk of developing AMD (such as those with
low MP, family history of AMD and smokers) and suffering
the associated visual losses and lifestyle effects of such visual
impairment within their lifetime. Research in the area of
AMD prevention, particularly around nutrition and macular
carotenoids, is ongoing and supports (albeit inconclusively
as of yet) the role of the macular carotenoids for AMD and
for the ‘at-risk’ patient. When making recommendations on
nutritional supplements, the optometrist should base such
recommendations on supporting and available scientific
studies on carotenoids/antioxidants and AMD. It is our view
that the scientific literature is in favour of a supplement that
contains all three macular carotenoids.
It is encouraging to see the optometry community reporting
many cases of improved AMD (albeit crudely assessed and
reported) following recommendation of nutritional eye
supplements. However, further work is required to understand
such benefits fully, in order to try to identify the type of
patient who could benefit most from such recommendations.
There are now several clinical trials underway investigating the
potential of nutritional supplementation for AMD, including
a major European-funded study about to commence in
Waterford, Ireland. These studies have the capacity to address
the outstanding issues more completely and provide more
definitive information on the role of MP supplements in AMD.
In conclusion, the optometrist who represents a very important
first line of eye care is advised to review the scientific literature
on this ever-growing topic regularly. Indeed, it is important
that the totality of the available evidence is examined, which,
for now, suggests a positive role for the macular carotenoids,
L, Z and meso-Z for patients at risk of, or presenting with, AMD.

Summary
Age-related macular degeneration (AMD) is the leading
cause of blind registration in the western world, and
the number of people with this condition continues to
rise due to the ageing population. AMD destroys central
vision and impairs quality of life in the elderly. Current
treatment options, while effective in some patients,
are costly and present a massive financial challenge
for Europe and its healthcare services. There is a clear
need, therefore, for attention to be directed towards
the prevention or delay of AMD and its progression. The
optometrist, who represents the first line of eye care,
is uniquely placed to implement such a prevention
strategy for AMD.
This paper reports and discusses findings from an online
AMD research survey, designed to investigate current
practice for AMD amongst optometric practitioners in
the Republic of Ireland and the UK.
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Biophys 504, 56–60
Loane E, Kelliher C, Beatty S et al. (2008) The rationale and
evidence base for a protective role of macular pigment in
age-related maculopathy. Br J Ophthalmol 92, 1163–8
Loughman J, Akkali MC, Beatty S et al. (2010) The relationship
between macular pigment and visual performance. Vision Res 50,
1249–56

4. Which of these techniques was most often employed to
check for the presence of AMD?

Nolan JM, Loughman J, Akkali MC et al. (2011) The impact of
macular pigment augmentation on visual performance in normal
subjects: COMPASS. Vision Res 51, 459–69

5. What percentage of respondents are currently
recommending eye supplements for patients at risk
of AMD?

Owen CG, Fletcher AE, Donoghue M et al. (2003) How big is the
burden of visual loss caused by age related macular degeneration
in the UK? Br J Ophthalmol 87, 312–17

(a)
(b)
(c)
(d)

Sommerburg O, Keunen JE, Bird AC et al. (1998) Fruits and
vegetables that are sources for lutein and zeaxanthin: the macular
pigment in human eyes. Br J Ophthalmol 82, 907–10
Tomany SC, Cruickshanks KJ, Klein R et al. (2004) Sunlight and the
10-year incidence of age-related maculopathy: the Beaver Dam
Eye Study. Arch Ophthalmol 122, 750–7
Trieschmann M, Beatty S, Nolan JM et al. (2007) Changes in
macular pigment optical density and serum concentrations of
its constituent carotenoids following supplemental lutein and
zeaxanthin: the LUNA study. Exp Eye Res 84, 718–28

Multiple choice questions
This paper is reference C-17733. Two points are available
for optometrists and therapeutics. Please use the inserted
answer sheet. Copies can be obtained from Optometry in
Practice Administration, PO Box 6, Skelmersdale, Lancashire
WN8 9FW. There is only one correct answer for each question.
1. For each decade over the age of 40 how much does the
amount of blindness and visual loss increase?
Twofold
Threefold
Fourfold
Fivefold

2. Vision of 6/12 or less is associated with which of
the following:
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Macular pigment consists of three dietary carotenoids
Meso -zeaxanthin is present in a conventional western diet
Lutein can be obtained from many foods
Macular pigment can filter blue light

(a)
(b)
(c)
(d)

Schork NJ (1997) Genetics of complex disease: approaches,
problems, and solutions. Am J Respir Crit Care Med 156, S103–9

(a)
(b)
(c)
(d)

(a)
(b)
(c)
(d)

Maoka T, Arai A, Shimizu M et al. (1986) The first isolation of
enantiomeric and meso-zeaxanthin in nature. Comp Biochem
Physiol B 83, 121–4

Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab
for neovascular age-related macular degeneration. N Engl J Med
355, 1419–31

(a)
(b)
(c)
(d)

3. Regarding macular carotenoids, which of the following
statements is incorrect?

Increased risk of falls
Depression
Loss of social independence
All of the above

Ophthalmoscopy
Retinal photography
Amsler grid
Measurement of macular pigment

90.6%
73.2%
52.8%
48.5%

6. Which of the following was the strongest influence
when deciding whether to recommend eye supplements to
a patient?
(a)
(b)
(c)
(d)

Presence of drusen
Presence of pigmentary changes
Family history of AMD
Signs of late AMD

7. What percentage of practices reported some improvement
in at least one of their AMD patients following
supplementation?
(a)
(b)
(c)
(d)

20%
22%
24%
26%

8. Which one of the following supplements showed the
highest improvement in AMD?
(a)
(b)
(c)
(d)

Macushield
ICaps
Ocuvite Lutein
Ocuvite Preservision

9. What percentage of patients currently have the capacity to
measure macular pigment in people at risk of AMD?
(a)
(b)
(c)
(d)

3.2%
3.7%
4.2%
4.7%

10. Regarding measuring macular pigment, which of the
following statements is incorrect?
(a) Heterochromic flicker photometry (HFP) is the gold
standard
(b) The Macuscope allows customisation of the method
(c) The M-POD can yield lower results compared to the
gold standard
(d) The clinical densitometer produces reliable and
reproducible results

Online AMD research study for optometrists: current practice in the Republic of Ireland and UK

11. Regarding eye supplements, which of the following
statements is incorrect?
(a) ICaps and Macushield were the two most commonly
recommended supplements
(b) Ocuvite Lutein has many supporting published studies
(c) Macushield has a growing body of evidence in support of
this supplement
(d) ICaps has many supporting published studies

•  your colleagues?

2. How might you assess/measure this impact?

12. Which combination of macular carotenoids is most
appropriate for patients at risk of, or presenting with, AMD?
(a)
(b)
(c)
(d)

Lutein and zeaxanthin
Lutein alone
Lutein and meso-zeaxanthin
Lutein, zeaxanthin and meso-zeaxanthin

CPD Exercise
Now update your CPD record with this article. If you have
completed the CET questions, the details for this article
can be downloaded from CETOptics (at the end of the
month). If you have not completed the CET questions
you can cut and paste the relevant details (title/learning
outcomes etc.) from the pdf copy of the article which is
posted on the College website.

To access CPD Online please click on the following link:
college-optometrists.org/cpd

Once you have downloaded the details of the article,
answer the reflective questions to complete the CPD
activity.
If you wish, you can type your reflections into the box
below and then copy them into your online record.

Reflection
1. What impact has your learning had, or might it have, on:
•  your patients or other service users (eg those who refer
patients to you, members of staff whom you supervise)?

•  yourself (improved knowledge, performance, confidence)?
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